Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
暂无分享,去创建一个
[1] P. Emery,et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. , 2006, Arthritis and rheumatism.
[2] R. Price,et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. , 2002, Arthritis and rheumatism.
[3] N. Miyasaka,et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. , 2004, Arthritis and rheumatism.
[4] Tocilizumab reduces disease activity in rheumatoid arthritis , 2004 .
[5] D. M. van der Heijde,et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab , 2007, Annals of the rheumatic diseases.
[6] L. Carmona,et al. Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. , 2004, The Journal of rheumatology.
[7] M. Genovese,et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. , 2008, Arthritis and rheumatism.
[8] D. Furst,et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study , 2005, Annals of the rheumatic diseases.
[9] F. Arnett. Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.
[10] M. Homma. [ACR preliminary definition, of improvement in rheumatoid arthritis]. , 1996, Ryumachi. [Rheumatism].
[11] J. Kremer,et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial , 2008, Annals of the rheumatic diseases.
[12] F. Breedveld,et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. , 2006, Arthritis and rheumatism.
[13] J J Anderson,et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.
[14] T. Kishimoto,et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. , 2003, The Journal of rheumatology.
[15] M. Prevoo,et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.
[16] Richard W. Martin,et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. , 2005, The Journal of rheumatology.
[17] J. Smolen,et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial , 2008, The Lancet.
[18] L. Klareskog,et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial , 2004, The Lancet.
[19] L. Moreland. Humanized anti-interleukin-6 receptor antibody , 2005 .
[20] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.
[21] Elizabeta Nemeth,et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. , 2004, The Journal of clinical investigation.
[22] F. Epstein,et al. Rheumatoid arthritis. Pathophysiology and implications for therapy. , 1990, The New England journal of medicine.
[23] T. Kishimoto,et al. Anti-interleukin 6 receptor antibody treatment in rheumatic disease , 2000, Annals of the rheumatic diseases.
[24] P. Cooper. Treatment of rheumatic disease. , 1975, Midwife, health visitor & community nurse.